This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2010 Jun;8(6):415-6.

Biomarkers: hypertension following anti-angiogenesis therapy

Affiliations

PMID: 20733551

Biomarkers: hypertension following anti-angiogenesis therapy

Brian I Rini. Clin Adv Hematol Oncol. 2010 Jun.

. 2010 Jun;8(6):415-6.

Author

Affiliation

¹ Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA.

PMID: 20733551

No abstract available

PubMed Disclaimer

Similar articles

Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?
van Heeckeren WJ, Ortiz J, Cooney MM, Remick SC. van Heeckeren WJ, et al. J Clin Oncol. 2007 Jul 20;25(21):2993-5. doi: 10.1200/JCO.2007.11.5113. J Clin Oncol. 2007. PMID: 17634476 No abstract available.
Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer.
Roukos DH, Tzakos A, Zografos G. Roukos DH, et al. Expert Rev Anticancer Ther. 2009 Oct;9(10):1413-6. doi: 10.1586/era.09.116. Expert Rev Anticancer Ther. 2009. PMID: 19828000 No abstract available.
Renal effects of anti-angiogenesis therapy: update for the internist.
Gurevich F, Perazella MA. Gurevich F, et al. Am J Med. 2009 Apr;122(4):322-8. doi: 10.1016/j.amjmed.2008.11.025. Am J Med. 2009. PMID: 19332223 Review.
Targeting angiogenesis in head and neck cancer.
Seiwert TY, Cohen EE. Seiwert TY, et al. Semin Oncol. 2008 Jun;35(3):274-85. doi: 10.1053/j.seminoncol.2008.03.005. Semin Oncol. 2008. PMID: 18544442 Review.
Angiogenesis inhibitors and hypertension: an emerging issue.
Sica DA. Sica DA. J Clin Oncol. 2006 Mar 20;24(9):1329-31. doi: 10.1200/JCO.2005.04.5740. Epub 2006 Jan 30. J Clin Oncol. 2006. PMID: 16446321 No abstract available.

See all similar articles

Cited by

Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea.
Baek SH, Kim H, Lee J, Kim DK, Oh KH, Kim YS, Han JS, Kim TM, Lee SH, Joo KW. Baek SH, et al. Korean J Intern Med. 2014 Jan;29(1):40-8. doi: 10.3904/kjim.2014.29.1.40. Epub 2014 Jan 2. Korean J Intern Med. 2014. PMID: 24574832 Free PMC article.
Novel concepts of antiangiogenic therapies in metastatic renal cell cancer.
Pichler R, Heidegger I. Pichler R, et al. Memo. 2017;10(4):206-212. doi: 10.1007/s12254-017-0344-2. Epub 2017 Aug 11. Memo. 2017. PMID: 29250198 Free PMC article. Review.
Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma.
Suttle AB, Ball HA, Molimard M, Hutson TE, Carpenter C, Rajagopalan D, Lin Y, Swann S, Amado R, Pandite L. Suttle AB, et al. Br J Cancer. 2014 Nov 11;111(10):1909-16. doi: 10.1038/bjc.2014.503. Epub 2014 Oct 28. Br J Cancer. 2014. PMID: 25349968 Free PMC article.
Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study.
Johnson AC, Matias M, Boyle H, Escudier B, Molinier A, Laguerre B, Helissey C, Brachet PE, Dugué AE, Mourey L, Coquan E, Joly F. Johnson AC, et al. BMC Cancer. 2017 May 22;17(1):355. doi: 10.1186/s12885-017-3312-7. BMC Cancer. 2017. PMID: 28532444 Free PMC article.
Future directions in renal cell carcinoma: 2011 and beyond.
Cho DC, Atkins MB. Cho DC, et al. Hematol Oncol Clin North Am. 2011 Aug;25(4):917-35. doi: 10.1016/j.hoc.2011.05.001. Hematol Oncol Clin North Am. 2011. PMID: 21763974 Free PMC article. Review.

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Medical
- MedlinePlus Health Information